These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14624619)

  • 1. Multivalent poly(ethylene glycol)-containing conjugates for in vivo antibody suppression.
    Jones DS; Branks MJ; Campbell MA; Cockerill KA; Hammaker JR; Kessler CA; Smith EM; Tao A; Ton-Nu HT; Xu T
    Bioconjug Chem; 2003; 14(6):1067-76. PubMed ID: 14624619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome.
    Cockerill KA; Smith E; Jones DS; Branks MJ; Hayag M; Victoria EJ; Linnik MD; Campbell MA
    Int Immunopharmacol; 2003 Nov; 3(12):1667-75. PubMed ID: 14555291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
    Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol).
    Vugmeyster Y; Entrican CA; Joyce AP; Lawrence-Henderson RF; Leary BA; Mahoney CS; Patel HK; Raso SW; Olland SH; Hegen M; Xu X
    Bioconjug Chem; 2012 Jul; 23(7):1452-62. PubMed ID: 22731748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response.
    Jones DS; Cockerill KA; Gamino CA; Hammaker JR; Hayag MS; Iverson GM; Linnik MD; McNeeley PA; Tedder ME; Ton-Nu HT; Victoria EJ
    Bioconjug Chem; 2001; 12(6):1012-20. PubMed ID: 11716694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method.
    Wie SI; Wie CW; Lee WY; Filion LG; Sehon AH; Akerblom E
    Int Arch Allergy Appl Immunol; 1981; 64(1):84-99. PubMed ID: 7450906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B.
    Conover CD; Zhao H; Longley CB; Shum KL; Greenwald RB
    Bioconjug Chem; 2003; 14(3):661-6. PubMed ID: 12757392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
    Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
    Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and physical characterization of poly(ethylene glycol)-gelatin conjugates.
    Kushibiki T; Matsuoka H; Tabata Y
    Biomacromolecules; 2004; 5(1):202-8. PubMed ID: 14715027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of pH-sensitive amphotericin B-poly(ethylene glycol) conjugates and study of their controlled release in vitro.
    Sedlák M; Pravda M; Staud F; Kubicová L; Týcová K; Ventura K
    Bioorg Med Chem; 2007 Jun; 15(12):4069-76. PubMed ID: 17434312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
    Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.
    Heyes J; Hall K; Tailor V; Lenz R; MacLachlan I
    J Control Release; 2006 May; 112(2):280-90. PubMed ID: 16603272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEG-Ara-C conjugates for controlled release.
    Schiavon O; Pasut G; Moro S; Orsolini P; Guiotto A; Veronese FM
    Eur J Med Chem; 2004 Feb; 39(2):123-33. PubMed ID: 14987821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and antimycobacterial property of PEG-bis(INH) conjugates.
    Kakkar D; Tiwari AK; Chuttani K; Khanna A; Datta A; Singh H; Mishra AK
    Chem Biol Drug Des; 2012 Aug; 80(2):245-53. PubMed ID: 22515497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery.
    Chandrasekar D; Sistla R; Ahmad FJ; Khar RK; Diwan PV
    J Biomed Mater Res A; 2007 Jul; 82(1):92-103. PubMed ID: 17269145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review.
    Greenwald RB; Conover CD; Choe YH
    Crit Rev Ther Drug Carrier Syst; 2000; 17(2):101-61. PubMed ID: 10820646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination.
    Greenwald RB; Yang K; Zhao H; Conover CD; Lee S; Filpula D
    Bioconjug Chem; 2003; 14(2):395-403. PubMed ID: 12643750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant.
    Yasuda S; Atsumi T; Matsuura E; Kaihara K; Yamamoto D; Ichikawa K; Koike T
    Arthritis Rheum; 2005 Jan; 52(1):212-8. PubMed ID: 15641049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity.
    Metselaar JM; Bruin P; de Boer LW; de Vringer T; Snel C; Oussoren C; Wauben MH; Crommelin DJ; Storm G; Hennink WE
    Bioconjug Chem; 2003; 14(6):1156-64. PubMed ID: 14624629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.